Molecular and Precision Medicine (MAP) Series
A five-part series, with each session including two expert presentations and a Q&A.
Overview
Video
Faculty
Series Description:
The goal of the inaugural MAP series was to educate health care providers and team members, including industry partners, about the basics of genomics, understanding genomic reports including variants of unknown significance, and therapeutic application. Ultimately, we sought to accelerate the clinical development and clinical application of precision diagnostics and therapies for patients with cancer and to improve the outcomes for patients who are battling this difficult-to-treat disease.
Learning Objectives:
- Identify the therapeutic strategies to target actionable oncogenic drivers in non-small cell lung cancer.
- Appraise the various alterations in the PI3K and MAPK pathway and potential therapeutic strategies.
- Review the role of tumor mutation burden and other tissue-agnostic biomarkers in mediating response to immunotherapy.
- Examine the components of antibody drug-conjugates and therapeutic role in solid tumors.
Complete Video Program
April 21, 2021
Pancancer Analysis of Whole Genomes
Gad Getz, PhD
Broad Institute/MGH Cancer Center
Kinase Pathway Targeted Therapeutics
Keith T. Flaherty, MD
MGH Cancer Center/Harvard Medical School
Moderator
Aditya Bardia, MD, MPH
Massachusetts General Hospital Cancer Center, Harvard Medical School
April 28, 2021
Genotyping Techniques and Reports
Geoff R. Oxnard, MD
Foundation Medicine
Germline and Ethical Considerations
Leif W. Ellisen, MD, PhD
MGH Cancer Center/Harvard Medical School
Moderator
Jochen Lennerz, MD
Center for Integrated Diagnostics, Massachusetts General Hospital
May 5, 2021
Targeting PI3K Pathway
Dejan Juric, MD
MGH/Termeer Center for Targeted Therapies
Plasma vs Tissue Genotyping: Debate
(Pro Tissue – Dr. Iafrate; Pro Plasma – Dr. Corcoran)
A. John Iafrate, MD
MGH/Harvard Medical School
Ryan B. Corcoran, MD, PhD
MGH Cancer Center/Harvard Medical School
Moderator
Aparna Parikh, MD, MS
Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center
May 12, 2021
Targeting ALK, ROS and Other Fusion Drivers
Alice T. Shaw, MD, PhD
Novartis
Targeting MET
Rebecca S. Heist, MD, MPH
MGH/Harvard Medical School
Moderator
Aaron Hata, MD, PhD
Massachusetts General Hospital
May 19, 2021
Role of Immunotherapy in the Era of Precision Medicine
Justin F. Gainor, MD
MGH Cancer Center/Harvard Medical School
Role of Antibody Drug Conjugates in the Era of Precision Medicine
David R. Spriggs, MD
MGH Cancer Center/Harvard Medical School
Moderator
Ryan J. Sullivan, MD
Massachusetts General Hospital Cancer Center
Program Directors
Bruce A. Chabner, MD
Massachusetts General Hospital Cancer Center, Harvard Medical School
Aditya Bardia, MD, MPH
Massachusetts General Hospital Cancer Center, Harvard Medical School
Presenters
Gad Getz, PhD
Broad Institute, Massachusetts General Hospital Cancer Center
Geoff R. Oxnard, MD
Foundation Medicine
Dejan Juric, MD
Massachusetts General Hospital Termeer Center for Targeted Therapies
Ryan B. Corcoran, MD, PhD
Massachusetts General Hospital Cancer Center, Harvard Medical School
Rebecca S. Heist, MD, MPH
Massachusetts General Hospital Cancer Center, Harvard Medical School
David R. Spriggs, MD
Massachusetts General Hospital Cancer Center, Harvard Medical School
Keith T. Flaherty, MD
Massachusetts General Hospital Cancer Center, Harvard Medical School
Leif W. Ellisen, MD, PhD
Massachusetts General Hospital Cancer Center, Harvard Medical School
A. John Iafrate, MD
Massachusetts General Hospital Cancer Center, Harvard Medical School
Alice T. Shaw, MD, PhD
Novartis
Justin F. Gainor, MD
Massachusetts General Hospital Cancer Center, Harvard Medical School
Moderators
Jochen Lennerz, MD
Center for Integrated Diagnostics, Massachusetts General Hospital
Aaron Hata, MD, PhD
Massachusetts General Hospital
Aparna Parikh, MD, MS
Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center
Ryan J. Sullivan, MD
Massachusetts General Hospital Cancer Center